Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to learn if BGB-11417 given alone or with dexamethasone and carfilzomib may help people with multiple myeloma. The people in this study have multiple myeloma that keeps growing after standard treatment. BGB-11417 blocks a protein called Bcl-2 that helps multiple myeloma cells to live and grow.
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
TL-895 blocks the action of an enzyme called Bruton's tyrosine kinase (BTK). Tyrosine kinases are involved in many cell functions, including signaling, growth, and division. The activation of BTK in mast cells may trigger ISM symptoms. TL-895 is taken orally (by mouth).
Researchers want to find the best dose of RYZ801 to give with RYZ811 in people with inoperable liver cancer. Inoperable means the cancer cannot be taken out with surgery. The people in this study have hepatocellular carcinoma (HCC) that makes high levels of a liver protein called GPC3.
Researchers want to find the best dose of ADCLEC.syn1 that can be used in people with leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even after treatment. There are currently no FDA-approved CAR T cell therapies for AML.
Researchers want to see if combining etentamig (ABBV-383) with iberdomide is a safe treatment for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. The researchers will assess different doses of these drugs to find the best dose for patients.
Imatinib is a standard long-term therapy for chronic myeloid leukemia (CML). Some people are able to stop taking imatinib after their CML is in remission, but sometimes it comes back and retreatment is needed. In this study, researchers want to see if adding the drug asciminib to imatinib therapy prior to a second attempt at stopping treatment will lead to prolonged treatment-free remission (no evidence of cancer after stopping therapy).
The purpose of this study is to find the highest doses of ruxolitinib and duvelisib when given together in patients with T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment. The Food and Drug Administration (FDA) has approved ruxolitinib as a treatment for myelofibrosis and polycythemia vera (other blood disorders). The FDA has approved duvelisib to treat follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The use of these two drugs together in this study is considered investigational.
However, most cancer recurrences happen within the first year of treatment. Long-term ICI therapy can also cause lasting side effects and be expensive. Doctors are therefore interested in finding ways to identify which patients can stop maintenance therapy sooner.
CAR T-cell therapy is a type of immunotherapy used to treat some people with lymphoma that has continued to grow despite prior treatment. The treatment involves using a patient's own T cells (a type of white blood cell), genetically modifying them in the laboratory to recognize a protein on cancer cells, and multiplying them. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body.
